EP2836217A4 - Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents - Google Patents

Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents

Info

Publication number
EP2836217A4
EP2836217A4 EP13775759.7A EP13775759A EP2836217A4 EP 2836217 A4 EP2836217 A4 EP 2836217A4 EP 13775759 A EP13775759 A EP 13775759A EP 2836217 A4 EP2836217 A4 EP 2836217A4
Authority
EP
European Patent Office
Prior art keywords
administration
compositions
treatment
methods
chemotherapeutic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13775759.7A
Other languages
German (de)
French (fr)
Other versions
EP2836217A1 (en
Inventor
John P Ford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asymmetric Therapeutics LLC
Original Assignee
Asymmetric Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/446,328 external-priority patent/US8653090B2/en
Application filed by Asymmetric Therapeutics LLC filed Critical Asymmetric Therapeutics LLC
Publication of EP2836217A1 publication Critical patent/EP2836217A1/en
Publication of EP2836217A4 publication Critical patent/EP2836217A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
EP13775759.7A 2012-04-13 2013-04-12 Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents Withdrawn EP2836217A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/446,328 US8653090B2 (en) 2008-03-12 2012-04-13 Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
PCT/US2013/036326 WO2013155385A1 (en) 2012-04-13 2013-04-12 Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents

Publications (2)

Publication Number Publication Date
EP2836217A1 EP2836217A1 (en) 2015-02-18
EP2836217A4 true EP2836217A4 (en) 2015-10-28

Family

ID=49328189

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13775759.7A Withdrawn EP2836217A4 (en) 2012-04-13 2013-04-12 Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents

Country Status (5)

Country Link
EP (1) EP2836217A4 (en)
JP (1) JP2015518000A (en)
CN (1) CN104394872A (en)
IN (1) IN2014DN09546A (en)
WO (1) WO2013155385A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10736557B2 (en) 2016-03-30 2020-08-11 Brain F.I.T. Imaging, LLC Methods and magnetic imaging devices to inventory human brain cortical function
EP3691523A4 (en) 2017-10-03 2020-12-09 Brain F.I.T. Imaging, LLC Methods and magnetic imaging devices to inventory human brain cortical function
CA3135689A1 (en) 2019-04-03 2020-10-08 Brain F.I.T. Imaging, LLC Methods and magnetic imaging devices to inventory human brain cortical function

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077365A2 (en) * 2004-02-12 2005-08-25 Istituto Superiore di Sanità Novel uses for proton pump inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130035A (en) * 1998-02-20 2000-10-10 Brusilow Enterprise Llc Use of orotidine monophosphate decarboxylase inhibition in a method for cancer screening
US6979688B2 (en) * 2002-02-12 2005-12-27 Ford John P Treatment method against side-effects of chemotherapy
US6995165B2 (en) * 2002-02-12 2006-02-07 Ford John P Methods, compositions, and kits for organ protection during systemic anticancer therapy
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
US7470672B2 (en) * 2006-07-31 2008-12-30 Savvipharm Inc. Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077365A2 (en) * 2004-02-12 2005-08-25 Istituto Superiore di Sanità Novel uses for proton pump inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2013155385A1 *

Also Published As

Publication number Publication date
EP2836217A1 (en) 2015-02-18
IN2014DN09546A (en) 2015-07-17
CN104394872A (en) 2015-03-04
WO2013155385A1 (en) 2013-10-17
JP2015518000A (en) 2015-06-25

Similar Documents

Publication Publication Date Title
HRP20190046T1 (en) Combination therapy for the treatment of cancer
HK1192758A1 (en) Phosphoramidate derivatives of 5-fluoro-2-deoxyuridine for use in the treatment of cancer 5--2-
IL273090B (en) Methods and compositions for the treatment of cancer
ZA201300692B (en) Administration of hypoxia activated prodrugs and antiagiogenic agents for the treatment of cancer
PL2818483T3 (en) Medicinal composition for treating and/or preventing cancer
PL2740795T3 (en) Cancer treatment and/or prevention drug composition
EP2740798A4 (en) Cancer treatment and/or prevention drug composition
EP2675469A4 (en) Compositions, devices and methods of use thereof for the treatment of cancers
EP2740793A4 (en) Drug composition for cancer treatment and/or prevention
IL238177A0 (en) Methods and compositions for the treatment of cancer
SI2861584T1 (en) Pyridopyrazine and naphthyridine derivatives for the treatment of cancer
EP2688594A4 (en) Methods and compositions for the treatment of cancer
EP2830633A4 (en) Combination therapy for the treatment of cancer
HK1201045A1 (en) Compositions and methods for the diagnosis and treatment of tumor
IL239374B (en) Compositions and methods for the treatment of brain cancers
IL275636A (en) Therapeutic combination for the treatment of cancer
SI2872176T1 (en) Carboranylporphyrins for use in the treatment of cancer
IL236321A0 (en) Combination therapy for the treatment of cancer and immunosuppression
EP2836217A4 (en) Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
PL2855475T3 (en) Alpha-carbolines for the treatment of cancer
IL245998A0 (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
HK1209111A1 (en) Quinone compounds and their uses for the treatment of cancer
IL233495A0 (en) Combination therapy for the treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141105

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150924

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/513 20060101ALI20150918BHEP

Ipc: A61K 31/519 20060101ALI20150918BHEP

Ipc: A61K 31/415 20060101ALI20150918BHEP

Ipc: A61K 31/52 20060101ALI20150918BHEP

Ipc: A61K 31/70 20060101AFI20150918BHEP

Ipc: A61K 31/4439 20060101ALI20150918BHEP

Ipc: A61P 35/00 20060101ALI20150918BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20180605